Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | SHBG | P04278 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804336 | 1.00 | ALDH1A1 (0.40) | ALDH1A1EPHX1CA12CA1CA2 | |
| SCHEMBL28849068 | 0.98 | ALDH1A1 (0.37) | ALDH1A1EPHX1CA12CA1CA2 | |
| SCHEMBL6769503 | 0.83 | ALDH1A1 (0.42) | ALDH1A1EPHX1CA12CA1CA2 | |
| SCHEMBL17715691 | 0.81 | ALDH1A1 (0.42) | ALDH1A1EPHX1CA12CA1CA2 | |
| SCHEMBL6808670 | 0.81 | ALDH1A1 (0.55) | ALDH1A1EPHX1CA12CA1CA2 | |
| SCHEMBL4742218 | 0.81 | ALDH1A1 (0.42) | ALDH1A1EPHX1CA12CA1CA2 | |
| SCHEMBL1208925 | 0.81 | ALDH1A1 (0.55) | ALDH1A1EPHX1CA12CA1CA2 | |
| SCHEMBL8651989 | 0.81 | ALDH1A1 (0.55) | ALDH1A1EPHX1CA12CA1CA2 | |
| SCHEMBL11468062 | 0.80 | ATM (0.42) | ALDH1A1EPHX1CA12CA1CA2 | |
| SCHEMBL13999779 | 0.79 | EPHX1 (0.48) | ALDH1A1EPHX1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040204367-A1 | Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis | G.D. SEARLE & CO. (US) | 2004-10-14 | — | — | US | disclosed |
| US-6613880-B2 | Autoimmune diseases; inflammatory conditions; competitive binding with Human Leukocyte Antigen displacing disease-inducing endogenous peptides | PHARMACIA CORPORATION | 2003-09-02 | — | — | US | disclosed |
| US-6552226-B1 | Rapid; low temperature; one pot synthesis; reduced catalytic quantities of such as lewis acid and tertiary amine; entiomerically pure products | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-04-22 | — | — | US | disclosed |
| WO-2002026683-A1 | TANDEM ACYL-CLAISEN REARRANGEMENT IN THE PREPARATION OF CHIRAL PRODUCTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-04-04 | — | — | WO | disclosed |
| US-6359174-B1 | REACTING ALLYL REACTANT WITH ACID CHLORIDE IN PRESENCE OF LEWIS ACID CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-03-19 | — | — | US | disclosed |
| US-20010027247-A1 | Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis | G.D. SEARLE & CO., (US) | 2001-10-04 | — | — | US | disclosed |
| WO-1996040753-A1 | PIPECOLIC ACID DERIVATIVES OF PROLINE THREONINE AMIDES USEFUL FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-4329296-A | Branched chain and cycloaliphatic esters of the androstane and oestrane series and pharmaceutical compositions containing same | AKZONA INCORPORATED (US) | 1982-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027247-A1 | Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis | ARGLU1, PRR12, PTMS | ALDH1A1 3744/4885EPHX1 2405/4885CA12 1213/4885 |
| US-20040204367-A1 | Pipecolic acid derivatives of proline threonine amides useful for the treatment of rheumatoid arthritis | ARGLU1, PRR12, PTMS | ALDH1A1 3744/4885EPHX1 2405/4885CA12 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.